Histone deacetylases and their inhibitors in kidney diseases.

IF 12.1 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Molecular Therapy Pub Date : 2025-04-21 DOI:10.1016/j.ymthe.2025.04.026

Yue Zheng,Tie-Ning Zhang,Peng-Hui Hao,Ni Yang,Yue Du

引用次数: 0

Abstract

Histone deacetylases (HDACs) have emerged as key regulators in the pathogenesis of various kidney diseases. This review explores recent advancements in HDAC research, focusing on their role in kidney development and their critical involvement in the progression of chronic kidney disease (CKD), acute kidney injury (AKI), autosomal dominant polycystic kidney disease (ADPKD), and diabetic kidney disease (DKD). It also discusses the therapeutic potential of HDAC inhibitors in treating these conditions. Various HDAC inhibitors have shown promise by targeting specific HDAC isoforms and modulating a range of biological pathways. Their protective effects include modulation of apoptosis, autophagy, inflammation, and fibrosis, underscoring their broad therapeutic potential for kidney diseases. However, further research is essential to improve the selectivity of HDAC inhibitors, minimize toxicity, overcome drug resistance, and enhance their pharmacokinetic properties. This review offers insights to guide future research and prevention strategies for kidney disease management.

查看原文本刊更多论文

肾病中的组蛋白去乙酰化酶及其抑制剂。

组蛋白去乙酰化酶（HDACs）已成为各种肾脏疾病发病机制中的关键调控因子。这篇综述探讨了 HDAC 研究的最新进展，重点是它们在肾脏发育中的作用，以及它们在慢性肾脏病 (CKD)、急性肾损伤 (AKI)、常染色体显性多囊肾病 (ADPKD) 和糖尿病肾病 (DKD) 进展过程中的关键作用。报告还讨论了 HDAC 抑制剂在治疗这些疾病方面的治疗潜力。各种 HDAC 抑制剂通过靶向特定 HDAC 异构体和调节一系列生物通路而显示出前景。这些抑制剂的保护作用包括调节细胞凋亡、自噬、炎症和纤维化，突出了其治疗肾脏疾病的广泛潜力。然而，进一步的研究对于提高 HDAC 抑制剂的选择性、降低毒性、克服耐药性以及增强其药代动力学特性至关重要。本综述为指导未来肾病治疗的研究和预防策略提供了见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Therapy 医学-生物工程与应用微生物

CiteScore

19.20

自引率

3.20%

发文量

357

审稿时长

3 months

期刊介绍： Molecular Therapy is the leading journal for research in gene transfer, vector development, stem cell manipulation, and therapeutic interventions. It covers a broad spectrum of topics including genetic and acquired disease correction, vaccine development, pre-clinical validation, safety/efficacy studies, and clinical trials. With a focus on advancing genetics, medicine, and biotechnology, Molecular Therapy publishes peer-reviewed research, reviews, and commentaries to showcase the latest advancements in the field. With an impressive impact factor of 12.4 in 2022, it continues to attract top-tier contributions.